Dynamics of SARS-CoV-2-specific Antibodies Among COVID19 Biobank Donors in Argentina

Overview

Journal Heliyon

Specialty Social Sciences

Date 2021 Oct 13

PMID 34642643

Citations 4

Authors

Yesica Longueira

Maria Laura Polo

Gabriela Turk

Natalia Laufer

Affiliations

Soon will be listed here.

Abstract

Biobanks are instrumental for accelerating research. Early in SARS-CoV-2 pandemic, the Argentinean Biobank of Infectious Diseases (BBEI) initiated the COVID19 collection and started its characterization. Blood samples from subjects with confirmed SARS-CoV-2 infection either admitted to health institutions or outpatients, were enrolled. Highly exposed seronegative individuals, were also enrolled. Longitudinal samples were obtained in a subset of donors, including persons who donated plasma for therapeutic purposes (plasma donors). SARS-CoV-2-specific IgM and IgG levels, IgG titers and IgG viral neutralization capacity were determined. Out of 825 donors, 57.1% were females and median age was 41 years (IQR 32-53 years). Donors were segregated as acute or convalescent donors, and mild versus moderate/severe disease donors. Seventy-eight percent showed seroconversion to SARS-CoV-2 specific antibodies. Specific IgM and IgG showed comparable positivity rates in acute donors. IgM detectability rate declined in convalescent donors while IgG detectability remained elevated in early (74,8%) and late (83%) convalescent donors. Among donors with follow-up samples, IgG levels seemed to decline more rapidly in plasma donors. IgG levels were higher with age, disease severity, number of symptoms, and more durable in moderate/severe disease donors. Levels and titers of anti-spike/RBD IgG strongly correlated with neutralization activity against WT virus. The BBEI-COVID19 collection serves a dual role in this SARS-CoV-2 global crisis. First, it feeds researchers and developers transferring samples and data to fuel research projects. Second, it generates highly needed local data to understand and frame the regional dynamics of the infection.

Citing Articles

Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.

Owusu-Boaitey N, Russell T, Meyerowitz-Katz G, Levin A, Herrera-Esposito D Euro Surveill. 2023; 28(21).

PMID: 37227301 PMC: 10283460. DOI: 10.2807/1560-7917.ES.2023.28.21.2200809.

SARS-CoV-2 humoral and cellular immune responses in COVID-19 convalescent individuals with HIV.

Giannone D, Vecchione M, Czernikier A, Polo M, Gonzalez Polo V, Cruces L J Infect. 2022; 85(3):334-363.

PMID: 35636532 PMC: 9135637. DOI: 10.1016/j.jinf.2022.05.026.

Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population.

Aijaz J, Hussain S, Naseer F, Kanani F, Anis S, Sarfaraz S Vaccines (Basel). 2022; 10(5).

PMID: 35632448 PMC: 9171576. DOI: 10.3390/vaccines10050692.

Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.

Blanco S, Konigheim B, Diaz A, Spinsanti L, Aguilar J, Rivarola M Vaccine. 2021; 40(5):811-818.

PMID: 34953609 PMC: 8685184. DOI: 10.1016/j.vaccine.2021.12.027.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

Nagoba B, Gavkare A, Jamadar N, Mumbre S, Selkar S . Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19. J Infect Public Health. 2020; 13(12):1818-1822. PMC: 7462592. DOI: 10.1016/j.jiph.2020.08.011. View

Rabinovich G, Geffner J . Facing up to the COVID-19 pandemic in Argentina. Nat Immunol. 2021; 22(3):264-265. DOI: 10.1038/s41590-021-00873-w. View

Schwarzkopf S, Krawczyk A, Knop D, Klump H, Heinold A, Heinemann F . Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG. Emerg Infect Dis. 2020; 27(1). DOI: 10.3201/2701.203772. View

Rejeki M, Sarnadi N, Wihastuti R, Fazharyasti V, Samin W, Yudhaputri F . Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries. EClinicalMedicine. 2021; 36:100931. PMC: 8175127. DOI: 10.1016/j.eclinm.2021.100931. View

Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P . Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect. 2020; 26(11):1557.e1-1557.e7. PMC: 7834107. DOI: 10.1016/j.cmi.2020.07.038. View

Suthar M, Zimmerman M, Kauffman R, Mantus G, Linderman S, Hudson W . Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep Med. 2020; 1(3):100040. PMC: 7276302. DOI: 10.1016/j.xcrm.2020.100040. View

Montgomery R, Zachary A, Racusen L, Leffell M, King K, Burdick J . Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000; 70(6):887-95. DOI: 10.1097/00007890-200009270-00006. View

10.

De Silvestro G, Gandini G, Fiorin F, Marson P, Barbone E, Frigato A . Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies. Transfus Apher Sci. 2021; 60(4):103154. PMC: 8103741. DOI: 10.1016/j.transci.2021.103154. View

11.

Chen Y, Zuiani A, Fischinger S, Mullur J, Atyeo C, Travers M . Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell. 2020; 183(6):1496-1507.e16. PMC: 7608032. DOI: 10.1016/j.cell.2020.10.051. View

12.

Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B . Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020; 136(6):755-759. PMC: 7414593. DOI: 10.1182/blood.2020007079. View

13.

Maine G, Lao K, Mallika Krishnan S, Afolayan-Oloye O, Fatemi S, Kumar S . Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. J Clin Virol. 2020; 133:104663. PMC: 7590643. DOI: 10.1016/j.jcv.2020.104663. View

14.

Perreault J, Tremblay T, Fournier M, Drouin M, Beaudoin-Bussieres G, Prevost J . Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood. 2020; 136(22):2588-2591. PMC: 7714093. DOI: 10.1182/blood.2020008367. View

15.

Angka L, Market M, Ardolino M, Auer R . Is innate immunity our best weapon for flattening the curve?. J Clin Invest. 2020; 130(8):3954-3956. PMC: 7410037. DOI: 10.1172/JCI140530. View

16.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

17.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

18.

Terpos E, Mentis A, Dimopoulos M . Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med. 2020; 383(17):1695. DOI: 10.1056/NEJMc2027051. View

19.

Rossi A, Ojeda D, Varese A, Sanchez L, Gonzalez Lopez Ledesma M, Mazzitelli I . Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Rep Med. 2021; 2(8):100359. PMC: 8266543. DOI: 10.1016/j.xcrm.2021.100359. View

20.

Ojeda D, Gonzalez Lopez Ledesma M, Pallares H, Costa Navarro G, Sanchez L, Perazzi B . Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog. 2021; 17(1):e1009161. PMC: 7808630. DOI: 10.1371/journal.ppat.1009161. View